Virtu Financial’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-93,668
Closed -$422K – 2012
2026
Q1
$422K Buy
+93,668
New +$488K 0.02% 639
2024
Q1
– Sell
-22,366
Closed -$428K – 1845
2023
Q4
$428K Buy
+22,366
New +$387K 0.03% 458
2019
Q4
$223K Buy
+8,176
New +$225K 0.02% 864
2019
Q2
– Sell
-7,061
Closed -$234K – 1711
2019
Q1
$234K Buy
+7,061
New +$215K 0.01% 920
2015
Q3
– Sell
-8,818
Closed -$300K – 374
2015
Q2
$300K Buy
+8,818
New +$300K 0.03% 260

Other funds holding MYGN

Virtu Financial's MYGN Position: Q2 2026 in Review

Virtu Financial sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 93,668 shares — an estimated $422K sold.

Virtu Financial first reported a position in MYGN in Q2 2015 and held it in 5 quarters. The position peaked at $428K in Q4 2023. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Virtu Financial reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 93,668 Myriad Genetics shares in Q2 2026, an estimated $422K.
  • Virtu Financial first reported a position in Myriad Genetics in Q2 2015 and held it in 5 quarters.
  • Virtu Financial's Myriad Genetics position peaked at $428K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.